Abstract
CA125 is a tumour marker test based on a monoclonal antibody against an antigen from an ovarian carcinoma cell line. Serum concentrations of CA125 were determined in 95 patients with pancreatic cancer and in 106 patients with benign pancreatic, biliary and hepatocellular diseases. The CA125 concentrations were compared with the CA19-9 and CEA levels. Almost half (45%) of the patients with pancreatic cancer had an elevated CA125 level (greater than 35 U ml-1). Elevated values were also found in benign diseases (24%), especially in patients with pancreatitis and benign hepatocellular diseases, but more seldom in extrahepatic cholestasis. It seems that CA125 is of limited value in the diagnosis of pancreatic cancer. Combination of the CA125 with the CA19-9 test increases the sensitivity only 6% as compared to the CA19-9 assay alone. There may, however, be a use for CA125 in differentiating between obstructive jaundice of benign and malignant origin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bast R. C., Jr, Feeney M., Lazarus H., Nadler L. M., Colvin R. B., Knapp R. C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. doi: 10.1172/JCI110380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bast R. C., Jr, Klug T. L., Schaetzl E., Lavin P., Niloff J. M., Greber T. F., Zurawski V. R., Jr, Knapp R. C. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984 Jul 1;149(5):553–559. doi: 10.1016/0002-9378(84)90035-8. [DOI] [PubMed] [Google Scholar]
- Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
- Canney P. A., Moore M., Wilkinson P. M., James R. D. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984 Dec;50(6):765–769. doi: 10.1038/bjc.1984.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Haglund C., Lindgren J., Roberts P. J., Nordling S. Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis. Br J Cancer. 1986 Feb;53(2):189–195. doi: 10.1038/bjc.1986.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Haglund C., Roberts P. J., Kuusela P., Scheinin T. M., Mäkelä O., Jalanko H. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer. 1986 Feb;53(2):197–202. doi: 10.1038/bjc.1986.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jalanko H., Kuusela P., Roberts P., Sipponen P., Haglund C. A., Mäkelä O. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol. 1984 Feb;37(2):218–222. doi: 10.1136/jcp.37.2.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kabawat S. E., Bast R. C., Jr, Bhan A. K., Welch W. R., Knapp R. C., Colvin R. B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2(3):275–285. doi: 10.1097/00004347-198303000-00005. [DOI] [PubMed] [Google Scholar]
- Klug T. L., Bast R. C., Jr, Niloff J. M., Knapp R. C., Zurawski V. R., Jr Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984 Mar;44(3):1048–1053. [PubMed] [Google Scholar]
- Ruibal A., Encabo G., Martinéz-Miralles E., Murcia C., Capdevila J. A., Salgado A., Martinéz-Vasquéz J. M. CA125 seric levels in non malignant pathologies. Bull Cancer. 1984;71(2):145–146. [PubMed] [Google Scholar]
- Rutanen E. M., Lindgren J., Sipponen P., Stenman U. P., Saksela E., Seppäla M. Carcinoembryonic antigen in malignant and nonmalignant gynecologic tumors: circulating levels and tissue localization. Cancer. 1978 Aug;42(2):581–590. doi: 10.1002/1097-0142(197808)42:2<581::aid-cncr2820420226>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]